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Abstract
Background: In a cross-sectional study in 403 healthy, independently living elderly men (mean age
78 years), we determined which are the main physiological determinants of functional ability in
the elderly, and which components of the somatotropic system contribute to the maintenance of func-
tional ability.
Methods: Functional ability was assessed by the number of problems in activities of daily living and by
a measure of physical performance. Other physical characteristics included leg extensor strength,
bone mineral density of total body and proximal femur, and body composition, including lean mass
and fat mass. Serum insulin-like growth factor (IGF)-I and its binding proteins (IGFBP) -1, -2 and
-3 concentrations were all measured by RIA.
Results: Muscle strength was related to a lower degree of disability. Further, it was positively related to
physical performance and bone mineral density (all P , 0:001). Fat mass influenced activities of daily
living and physical performance negatively and bone mineral density positively (all P , 0:001).
Serum concentrations of IGF-I and IGFBP-3 were not related to any of the physical characteristics.
High serum IGFBP-2 concentrations were related to a higher degree of disability ðP , 0:001Þ;
a lower physical performance ðP ¼ 0:006Þ; muscle strength ðP ¼ 0:002Þ; bone mineral density of
proximal femur ðP ¼ 0:007Þ; lean mass and fat mass (both P , 0:001). Serum insulin and IGFBP-
1 concentrations were independently, positively related to lean mass ðP ¼ 0:003Þ and fat mass
ðP , 0:001Þ.
Conclusions: In independently living elderly men, functional ability appears to be determined by
muscle strength (positive) and fat mass (negative). Low serum IGFBP-2 concentrations are a powerful
indicator for overall good physical functional status, probably inversely reflecting the integrated sum
of nutrition and the biological effects of growth hormone, IGF-I and insulin.
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Introduction
There is considerable variation in the effects of aging in
healthy individuals, with some persons exhibiting
extensive decline in physiological functions with age
and others little or none. This suggests that there are
usual and successful patterns of aging (1). Genetic
factors, lifestyle, and societal investments in a safe
and healthful environment are important aspects of
successful aging (2). Traditionally, the aging process
has been considered to be physiological and unavoid-
able. Loss of muscle mass and strength are important
predictors of a decrease in physical performance (3).
Physical frailty, which is defined as ‘a state of reduced
physiologic reserves associated with increased suscepti-
bility to disability’ (4), frequently occurs towards the
end of life and often results in the loss of independence.
In recent years it has become evident that it might not
be necessary to accept the grim stereotype of aging as
an unalterable process of decline and loss (3, 4).
Prevention of loss of physical functions can be achieved
by exercise (3), while hormone replacement with
growth hormone (5–8) in the elderly has been
demonstrated to improve physical performance
in selected groups of elderly individuals. Also, data
have recently been reported which suggest that
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the insulin-like growth factor (IGF)/IGF-binding protein
(IGFBP) system might be related to the presence or
development of prostate malignancies (9).
With regard to the study of the age-related decline of
physical function and its relationships with the endo-
crine system, we investigated two central questions in
the present study. First, which are the main physiologi-
cal determinants of functional ability in the elderly and
secondly, which components of the somatotropic
system contribute to the maintenance of functional
ability. In addition, a possible relationship between
prostate disorders and serum concentrations of these
hormones was studied. We have investigated these
questions in a cross-sectional study in 403 healthy,
independently living elderly men.
Subjects and methods
Subjects
A cross-sectional, single-center study was conducted in
403 independently living men, aged 70 years and older.
Names and addresses of all male inhabitants 70 years
and older were drawn from the municipal register of
Zoetermeer, a medium-sized town in the mid-western
part of the Netherlands. Of a total of 1567 men invited
to participate, 886 men did not respond to the mailed
invitation in which it was mentioned that only subjects
who lived independently and had no severe mobility
problems could participate. After exclusion of subjects
who did not live independently and subjects who were
not physically or mentally able to visit the study
center independently, eventually 403 men participated
(25.7%). The main reason not to participate among the
respondents was because they were currently under the
care of a medical specialist or general practitioner
(28%), while 16% were excluded on the basis of physi-
cal (10%) or mental (6%) problems. Participants signed
an informed consent. The study has been approved by
the Medical Ethics Committee of the Erasmus University
Hospital, Rotterdam. No additional health-related
eligibility criteria were used. A number of participants
were taking medication for chronic illnesses, including
hypertension ðn ¼ 96Þ and mild congestive heart
failure ðn ¼ 28Þ: However, in retrospect, none of the
medications influenced the relationships described in
this study. Some of the illnesses, for example mild
knee pain ðn ¼ 79Þ; influenced the physical character-
istics measured, but they did not change the relations
between the physical characteristics, nor between the
circulating hormone levels and the physical character-
istics reported in this study.
Hormone measurements
Blood samples were collected in the morning after an
overnight fast. Serum was separated by centrifugation
and was deeply frozen. The period of storage
at 240 8C varied from 0 to 5 months. Total IGF-I was
measured by an IGFBP-blocked radioimmunoassay
(RIA) as described previously (10). IGFBP-1, IGFBP-2
and IGFBP-3 were determined by RIA as described pre-
viously (11 –13). The IGF-I/IGFBP-3 ratio (IGF/BP3)
was calculated. Insulin was measured by a commer-
cially available RIA (Pharmacia, Freyburg, Germany).
Physical characteristics
Physical performance Lower extremity function, or
physical performance, was assessed as described by
Guralnik et al. (14), including measurements of
standing balance, walking speed and ability to rise
from a chair. The three tests of standing balance were
considered in hierarchical difficulty by assigning a
single score of 0 to 4 for standing balance. For the
8-foot walk and repeated chair stands, those who
could not complete the task were assigned a score of
0. Those completing the task were assigned scores of
1 to 4, corresponding to the quartiles of time needed
to complete the task, with the fastest times scored as
4. A summary performance scale was created by
summing the category scores for the walking,
chairstand, and balance tests, which ranged from
0 (worst performance) to 12 (best performance).
Mean scores of the three tests as well as of the summary
performance scale measured in this study were
comparable to those reported in subjects of the same
age group investigated by Guralnik et al. (14).
Activities of daily living (ADL) Self-reported disabil-
ity or satisfaction in performing activities of daily living
was assessed by a self-administered questionnaire modi-
fied from the Stanford Health Assessment Questionnaire
as described by Pincus et al. (15). A score of 8 points
was obtained if the participants reported no problems
in activities of daily living, needed no help and when
there was no difference compared with the situation
6 months ago. A minimum score of 0 was given if
participants improved compared with 6 months
previously, while a maximum score of 36 points was
assigned to participants who reported severe problems
in activities of daily living, needed help and had more
problems in activities of daily living compared with 6
months ago. The lower the points measured in this
ADL score, the lower the degree of disability.
The Mini-Mental State Exam was used to determine
cognitive function (16).
Muscle strength Isometric leg extensor strength was
measured as described by Hsieh and Phillips using the
Hoggan MicroFET hand-held dynamometer (17). The
measurement requires that the participant, in a
seated position, pushes the dynamometer, which is
held at the tibia preferably 33 cm below the knee
joint, with maximal strength. The investigator holds
the dynamometer in the hand with an extended arm
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and pushes back until the breaking point is reached.
The measurements were carried out in two positions
and on both legs. During the first series of measure-
ments the leg was held in 1208 extension and during
the second series of measurements the leg was in an
extended position (1808). During the first series of
measurements the participant holds a device over the
leg tested, which keeps the leg at exactly 1208. The
measurements were done three times and the maxi-
mum performance at each position was recorded. To
obtain one measure of leg muscle strength, ‘maximum
leg extensor strength’ was defined as the maximum
strength for the right or left leg in a position of 1208.
Statistical analyses were based on the physical unit
measurement, moments (Nm), obtained by multiplying
the maximum strength (in Newton (N)) and the
distance of the dynamometer to the knee joint (in
meters (m)).
Bone mineral density and body composition Total
body bone mineral density was measured using dual
energy X-ray absorptiometry (DXA, Lunar, Madison,
WI, USA), as were hip bone mineral densities at the
femoral neck, trochanter and Ward’s triangle. In
addition, total lean body mass and fat mass were
measured (18, 19). Quality control, including cali-
bration, was performed routinely every morning for
DXA, using the standard provided by the manufacturer.
Height and weight were measured in the standing
position without shoes. Body mass index was calculated
as the weight in kilograms divided by the square of the
height in meters.
Measurements of prostate Medical history of signs of
enlarged prostate were obtained. Rectal examination
was performed. Prostate-specific antigen (PSA) was
determined by a commercially available kit.
Data analyses
Results are expressed, unless otherwise stated, as
means and standard deviation with the interquartile
(IQ) range. Variables which were not normally
distributed were logarithmically transformed. Relations
between variables were assessed using linear
regression for continuous variables, stated as linear
regression coefficient (b) and standard errors. Multiple
regression analysis was used to adjust for age and body
mass index, as well as to assess the contribution of
different independent variables to the dependent vari-
able. Partial correlations between variables were
assessed using Pearson’s product r. Unless otherwise
mentioned, all analyses are done after adjustment for
age. Analyses were performed using the Stata statistical
package (StataCorp. 1997, Stata Statistical Software:
release 5.0, Texas, USA).
Results
Characteristics of the study population are given in
Table 1. Mean age of the study population was
77.8 years (standard deviation 3.58).
Relationships between age and the different physi-
cal characteristics Physical performance, muscle
strength, bone mineral density, lean body mass and
fat mass all decreased with age (Table 2). With increas-
ing age, more limitations in activities of daily living
were reported.
Relationships among the different physical
characteristics Relationships among the different
physical characteristics, estimated by linear regression
analysis, are illustrated in Fig. 1. Subjects that scored
better in the physical performance test had significantly
less problems in activities of daily living (i.e. a lower
disability) and significantly higher bone mineral density
(at all sites measured). Muscle strength was positively,
independently related to the physical performance
score and bone mineral density at all sites measured,
while muscle strength and the number of problems
in activities of daily living were inversely related.
Table 1 Descriptive data of the study population.
Means S.D. IQ-range
Age (years) 77.8 3.6 75–80
Body mass index (kg/m2) 25.5 3.0 23.3–27.3
Physical performance
(points)
8.5 2.4 7–10
Activities of daily living
(points)
10.7 4.3 8–12
Total body bone mineral density
(g/cm2)
1.17 0.10 1.11–1.23
Femoral neck bone mineral density
(g/cm2)
0.88 0.14 0.78–0.97
Femoral ward bone mineral density
(g/cm2)
0.72 0.16 0.60–0.82
Femoral trochanter bone mineral
density (g/cm2)
0.85 0.15 0.76–0.94
Total fat mass (kg) 21.2 6.4 17.4–24.5
Total lean mass (kg) 51.7 5.6 47.8–55.5
Maximum leg extensor
strength (Nm)
103.2 20.9 89.4–117.1
Table 2 Relations between physical characteristics and age.
b 6S.E. P
Physical performance score (points/year) 20.22 ^0.03 ,0.001
Activities in daily living (log) (points/year) 0.01 ^0.005 0.02
Total body bone mineral density
(g/cm2/year)
20.01 ^0.001 ,0.001
Total fat mass (kg/year) 20.18 ^0.09 0.05
Total lean mass (kg/year) 20.38 ^0.08 ,0.001
Maximum leg extensor strength (Nm/year) 21.54 ^0.28 ,0.001
b regression coefficient denotes changes in unit per year. For example:
Physical performance score decreases 0.22 point per year.
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This implies that subjects with high muscle strength
reported significantly less problems with activities of
daily living (lower disability), scored significantly
better in the physical performance test and had
significantly higher bone mineral density compared
with subjects with low muscle strength. Further, lean
body mass was strongly associated with muscle
strength.
Fat mass was inversely related to the physical
performance score, but independently positive with
problems in activities of daily living and total body as
well as proximal femur bone mineral density. This
implies that subjects with a high fat mass scored signifi-
cantly lower on the physical performance test, had
more problems with activities of daily living, but had
significantly higher bone mineral density compared
with subjects with low fat mass.
Relations between the hormones and age The
summarized values of the hormones are presented
in Table 3. Serum concentrations of IGF-I and its
binding protein, IGFBP-3, decreased with age (b ¼
20:85^0:41ðmg=lÞ=year; P ¼ 0:04; and b ¼ 20:07^
0:01ðmg=lÞ=year; P , 0:001 respectively). Serum con-
centrations of IGFBP-1 and IGFBP-2 increased with age
(b ¼ 0:03^0:006ðmg=lÞ=year; P , 0:001 and b ¼
0:26^0:04ðmg=lÞ=year; P , 0:001 respectively).
Relationships amongst serum somatotropic
hormone concentrations Serum IGF-I and IGFBP-3
concentrations were strongly and positively related
ðr ¼ 0:53; P , 0:001Þ: Serum IGF-I concentrations
were inversely related to those of IGFBP-1
ðr ¼ 20:17; P , 0:001Þ and IGFBP-2 ðr ¼ 20:19;
P , 0:001Þ: However, as the IGFBP-1 and IGFBP-2
concentrations were interrelated ðr ¼ 0:49; P ,
0:001Þ; a multiple regression analysis including
IGFBP-1, as well as IGFBP-2, was performed. In this
analysis serum IGF-I levels remained related only to
those of IGFBP-2. The relationships between serum
concentrations of IGFBP-3 and those of IGFBP-1 and
IGFBP-2 respectively, were dependent on IGF-I. Insulin
concentrations were independently related to those of
IGFBP-1 and IGFBP-2 (r ¼ 20:30 and r ¼ 20:28;
P , 0:001 respectively).
Figure 1 Relationships between the physical characteristics monitored in this study. b denotes linear regression coefficient e.g. physical
performance increases 0:05^0:005 point per Nm muscle strength. *P , 0:001: Since physical performance, activities in daily living,
bone mineral density and muscle strength were all associated with body mass index, analyses including these parameters were carried
out after adjustment for body mass index (and age). Activities of daily living were not normally distributed; therefore activities of daily liv-
ing were included in the analyses after logarithmic transformation. The linear regression coefficient of the relationship between muscle
strength and activities of daily living is negative: the lowest scores in activities of daily living (i.e. few problems) were reported in men
with the highest muscle strength. Thus, a higher muscle strength is associated with a better performance in activities of daily living and
therefore with less disability. Part of the relationship between physical performance and bone mineral density was explained through
muscle strength.
Table 3 Summarized values of serum hormone concentrations.
Mean S.D. IQ-range
IGF-I (mg/l) 100.9 29.2 81.2–118.9
IGFBP-1 (mg/l) 31.7 15.5 21.2–38.6
IGFBP-2 (mg/l) 0.62 0.32 0.40–0.76
IGFBP-3 (mg/l) 2.59 0.70 2.09–3.04
Insulin (IU/l) 8.91 4.25 6.07–10.5
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Serum IGF-I and the binding proteins in relation to
physical characteristics Serum IGF-I and IGFBP-3
concentrations were not directly related to any of the
physical characteristics studied. In contrast, serum
IGFBP-2 levels were significantly, inversely related to
virtually all the variables measured including femur
bone mineral density, except for total body bone mineral
density (Fig. 2). As IGFBP-2 levels were strongly related
to body mass index ðb ¼ 24:00^0:45ðkg=m2Þ=ðmg=lÞ;
P , 0:001Þ; all analyses were repeated after adjustment
for body mass index (except for lean and fat mass).
Physical performance scores decreased 1:13^0:41
points per mg/l increase in IGFBP-2 ðP ¼ 0:005Þ:
Significantly more problems in activities of daily living
were reported with increasing serum IGFBP-2 concen-
trations (log transformed b ¼ 0:19^0:06 points/(mg/l),
P , 0:001Þ: Furthermore, muscle strength decreased
11:33^3:51 Nm per mg/l increase in IGFBP-2 ðP ¼
0:001Þ: Bone mineral density of the neck region
decreased 0:07^0:03 g=cm2 per mg/l increase in
IGFBP-2 ðP ¼ 0:005Þ: In addition, both lean body mass
and fat mass were lower in individuals with higher
IGFBP-2 concentrations (respectively b ¼ 24:09^
0:88 kg=ðmg=lÞ; and b ¼ 25:58^0:90 kg=ðmg=lÞ; both
P , 0:001). The inverse relationship between IGFBP-2
and physical performance was explained through the
inverse relationship between IGFBP-2 and muscle
strength. All the other relationships were independent
of each other.
Serum IGFBP-1 levels were inversely related to physi-
cal performance scores, fat mass and lean body mass,
and positively related to problems in activities of daily
living. However, serum IGFBP-1 and -2 levels were posi-
tively related and the relationships between IGFBP-1
and physical performance and activities in daily living,
respectively, were no longer significant after adjustment
for IGFBP-2. The relationships between IGFBP-1 and fat
mass and lean body mass, respectively, were indepen-
dent of IGFBP-2 (b ¼ 20:14^0:02 kg=ðmg=lÞ and
b ¼ 20:09^0:02 kg=ðmg=lÞ; P , 0:001 respectively).
Serum insulin concentrations were positively, and
independent of serum IGFBP-1 and IGFBP-2 con-
centrations, related to lean body mass as well as fat
mass (b ¼ 0:23^0:06 kg=ðIU=lÞ and b ¼ 0:40^
0:06 kg=ðIU=lÞ; P , 0:001 respectively).
Relationship between measurements of the IGF-
system and the prostate Subjects with a medical his-
tory of an enlarged prostate ðn ¼ 120Þ or with an
enlarged prostate at palpation ðn ¼ 95Þ did not have
circulating IGF-I, IGFBP-1, -2, -3 and IGF/BP3 ratio
concentrations which differed from the other subjects.
In addition, subjects with a suspicion of prostate malig-
nancy at palpation ðn ¼ 19Þ or a PSA level above
10 ng/ml ðn ¼ 34Þ did not have different IGF-I,
IGFBP-1, -2 and -3 concentrations or IGF/BP3 ratio
compared with the other subjects. Serum PSA concen-
trations were also not related to IGF-I, IGFBP-1, -2, -3
Figure 2 Relationships between serum concentrations of IGFBP-2, IGFBP-1, and insulin with the characteristics of physical function.
The effects of all hormones mentioned in this figure were independent of each other.
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and the IGF/BP3 ratio in a linear regression analysis.
The proportion of subjects with clinical symptoms of
an enlarged prostate, an enlarged prostate at palpation,
or PSA levels above 10 ng/ml was not different in quar-
tiles of IGF-I, IGFBP-1, -2, -3 and IGF/BP3 ratio.
The 35 subjects with a malignancy in their medical
history did not have serum IGFBP-2 concentrations
which differed from those of the other subjects.
Discussion
To appreciate the findings of this study, some aspects
need to be discussed. In evaluating the physical func-
tional status of the elderly, the choice of the best
approach to measurement remains uncertain. The
main clinical correlate used in this study is functional
ability, self-reported as well as objectively assessed as
a physical performance score using the approach pro-
posed by Guralnik et al. (14). Guralnik demonstrated
that a short battery of performance measures of lower
extremity function predicts mortality and loss of inde-
pendence amongst older persons. In addition, bone
mineral density, muscle strength and body composition
were measured as physical characteristics. Overall
physical function, as well as cognitive function in this
group of elderly men were relatively good. Only 30 indi-
viduals scored less then 24 points in the mini-mental
state exam, which indicates mild cognitive impairment.
In less selected populations with a broader range
of functional ability associations are likely to be, if
anything, stronger.
In the present work two major questions in the study
of the age-related decline of physical function were
addressed. With regard to the first question asked, our
findings in this large population of independently
living elderly men suggest that high muscle strength
and low fat mass are independent determinants of func-
tional ability. This finding agrees with other studies,
which demonstrated that muscle strength is indepen-
dently and positively related to physical performance
(3, 20) and to bone mineral density (21, 22), and inver-
sely related to the number of problems in activities of
daily living. Fat mass, on the other hand, is inversely
related to physical performance and restricted activities
in daily living, but positively related to bone mineral
density. This latter relationship probably reflects the
effect of hormones, such as estradiol or insulin, or
simply the effects of mechanical loading. These obser-
vations, as well as the other significant relationships
found in this study, led us to prepare a diagram repre-
senting the relationships between activities in daily
living, physical performance, bone mineral density,
muscle strength and body composition, as summarized
in Fig. 1.
Some of the age-related physiological changes may
be influenced by the activity of the endocrine system
(23, 24). In this population, physical function declines
with age. In parallel, serum IGF-I and IGFBP-3 concen-
trations significantly decreased with age, while those of
IGFBP-1 and IGFBP-2 increased. With regard to the
second question, e.g. which components of the somato-
tropic system contribute to the maintenance of func-
tional ability, we found no correlation between serum
IGF-I or IGFBP-3 concentrations on the one hand and
measures of functional ability, muscle strength, bone
mass and body composition on the other. This finding
agrees with previous reports (25 –30). We did,
however, demonstrate highly significant inverse
relationships between serum IGFBP-2 concentrations
and virtually all the physical characteristics measured.
IGFBP-2 is present in the human serum in very high
concentrations. In adult life, IGFBP-2 probably acts to
inhibit the biological effects of IGF-I (31). IGFBP-2 is
regulated by several mechanisms. It decreases after
birth until puberty, after which it gradually increases
again, especially after the age of 60 (12, 32). At age
80, concentrations are nearly twice as high as in
young adults (0.60 mg/l vs 0.35 mg/l). Therefore, the
decline in functional ability and the increase in serum
IGFBP-2 concentrations proceed in parallel. The precise
mechanisms regulating IGFBP-2 concentrations
remain unclear, although it is recognized that serum
IGFBP-2 concentrations are higher during starvation,
fasting and protein restriction, as well as in growth hor-
mone deficiency (33 –35), while they respond with a
decrease during growth hormone treatment (36, 37).
In this study, serum IGFBP-2 levels were strongly inver-
sely related to serum albumin concentration (data not
shown), which is generally regarded as a measure of
nutritional status (38). In addition, IGF-I appears to
be a regulator of IGFBP-2, since IGF-I administration
increases its serum levels (39), possibly, however, via
a suppression of growth hormone secretion (40).
Finally, insulin has been proposed as a regulator of
IGFBP-2, although evidence is not yet clear-cut (41).
In this study, serum IGF-I, IGFBP-3 as well as fasting
insulin concentrations were all inversely related to
IGFBP-2 as well. Insulin, which is considered to be an
anabolic hormone, was independent of IGFBP-2,
related to fat mass and lean mass only. Low serum
IGFBP-2 concentrations seem to be related to an ana-
bolic state and turn out to be a powerful indicator of
overall good physical functional status in elderly men.
We suggest that serum IGFBP-2 concentrations inver-
sely reflect the integrated sum of the nutritional state,
as well as the biological effects of growth hormone,
IGF-I, and insulin.
As IGFBP-2 concentrations have been reported to be
elevated in patients with several malignant tumors
(42, 43), in particular prostate carcinoma (39), one
might hypothesize that the association between
IGFBP-2 and functional ability is dependent on the pre-
sence of prostate malignancies. However, even within
the group of individuals with elevated PSA levels,
there was no relation between IGFBP-2 and PSA,
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or other prostate abnormalities. Additionally, in agree-
ment with Ho and Baxter, we did not find abnormal
IGFBP-2 concentrations in subjects with an enlarged
prostate (44). Consequently, from our study, we do
not have any indication that IGFBP-2 is produced by
the prostate. This implies that the relationships
between IGFBP-2 and the physical characteristics are
not dependent on the presence of prostate hypertropy
or malignancy.
In conclusion, muscle strength and functional ability
are considered to be the key characteristics of physical
functional status in independently living elderly men.
Functional ability appears to be determined by muscle
strength (positive) and fat mass (negative). The more
marked the functional ability, the higher the bone min-
eral density. Low serum IGFBP-2 concentrations are a
powerful indicator for an overall good physical func-
tional status, probably inversely reflecting the inte-
grated sum of nutritional status as well as of the
biological effects of growth hormone, IGF-I and insulin.
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